期刊文献+

原发性高血压左心室肥厚患者纤溶功能的变化 被引量:26

下载PDF
导出
摘要 目的了解高血压左心室肥厚(LVH)患者血清溶栓功能指标的变化情况及其临床意义。方法对40例 LVH 患者血清 P 选择素(Ps)、组织型纤溶酶原激活物(tPA)、纤溶酶原激活物抑制物(PAI)和血管性血友病因子(vWF)水平进行检测,并与30例健康体检者和45例高血压非左心室肥厚者(NLVH)比较。结果 LVH 组血清 Ps[(38.3±11.63)pg/L]、PAI[(1.5±0.6)Au/mL]和 vWF[(187.3±56.6)%]高于 NLVH 组[Ps(31.7±10.6)pg/L、PAI(0.8±0.3)Au/mL、vWF(127.8±36.4)%],NLVH 组上述指标又高于对照组[Ps(22.5±12.4)pg/L、PAI(0.6±0.3)Au/mL、vWF(98.5±34.8)%](P<0.01);tPA 水平分别为:LVH 组(0.3±0.3)、NLVH 组(0.7±0.4)、对照组(1.0±0.5)μg/L,LVH 组 tPA 低于 NLVH 组,NLVH 组又低于对照组(P<0.01)。结论原发性高血压 LVH 患者的抗凝作用减弱、血小板黏附与聚集以及纤溶活性下降,这些变化可能与此病常见的并发心脑血管意外的发生与发展有关。
出处 《中华高血压杂志》 CAS CSCD 北大核心 2008年第9期843-844,共2页 Chinese Journal of Hypertension
基金 广西科学研究与技术开发计划项目(合同编号:桂科基0141028) 广西教育厅科研资助项目(项目编号:2007101x147)
  • 相关文献

参考文献6

  • 1马宏,张七一.原发性高血压血栓前状态分子标志物的研究[J].山西医药杂志,2005,34(8):628-631. 被引量:3
  • 2肖琳玲,邓万俊.组织多普勒成像测定Tei指数评价高血压患者左室功能[J].中华高血压杂志,2006,14(12):1011-1012. 被引量:10
  • 3[3]Kannel WB,Wolf PA.Peripheral and cerebral atherothrornbosis and cardiovascular event s in different vascular territories:insightsfrom the Framingham study[J].Curr Atheroscler Rep,2006,8:317-323.
  • 4[4]Finsterer J,St(o)llberger C,Blazek G.Neuromuscular implications in left ventricular hypertrabeculation/noncompaction[J].Int J Cardiol,2006,28:288-300.
  • 5[5]Benz K,Amann K,Dittrich K,et al.Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis[J].Pediatr Nephrol,2007,22,2125-2128.
  • 6[6]Rozenberg VD,Nepomnyashchikh LM.Pathomorphology of variant relationships between left ventricle and interventricular septum in hypertensive heart[J].Bull Exp Biol Med,2007,144:103-107.

二级参考文献12

  • 1[1]LaCorte JC,Cabreriza SE,Rabkin DG,et al.Correlation of the Tei index with invasive measurements of ventricular function in a porcine model[J].J Am Soc Echocardiogr,2003,16:442-447.
  • 2[2]Yilmaz R,Celik S,Baykan M,et al.Pulsed wave tissue Doppler derived myocardial performance index for the assessment of left ventricular thrombus formation risk after acute myocardial infarction[J].Am Heart J,2004,148:1102-1108.
  • 3[3]Keser N,Yildiz S,Kurtog N,Dindar L.Modified Tei index:a promising parameter in essential hypertension[J].Echocardiography,2005,22:296-304.
  • 4Califano F,Giovanniello T,Pantone P,et al.Clinical importance of thrombomodulin serum levels.Eur Rev Med Pharmacol Sci,2000,4:59-66.
  • 5Borawski J,Mysliwiec M. Soluble thrombomodulin:a marker of endothelial injury,an antithrombotic angent,or both? Med Sci Monit,2001,7:785-786.
  • 6Sadler JE.Thrombomodulin structure and function.Thromb Haemost,1997,78:392-395.
  • 7Galatius SS,Wroblewski H,Vibeke BS,et al.Endothelin and Von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy:different stimuli for release before and after heart transplantation.Am Heart J,1999,137:549-554.
  • 8Kloczko J.Von Willebrand factor antigen and fibronection in essential hypertension.Thromb Res,1995,79:331-336.
  • 9Blann AD,Dobrotova M,Kubisz P,et al.Von Willebrand factor,soluble P-selectin,tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis.Thromb Haemost,1995,74(2):626-630.
  • 10Nofer JR,Tepel M,Kefrel B,et al.Low-density lipoproteins inhibit the Na^+/H^+ antiport in human platelets:a novel mechanism enhancing platelet activity in hypercholesterolemia.Circulation,1997,95:1370-1377.

共引文献11

同被引文献193

引证文献26

二级引证文献125

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部